Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Healthtrust
Teva
Chinese Patent Office
Daiichi Sankyo
Merck
AstraZeneca
Cerilliant

Generated: September 20, 2018

DrugPatentWatch Database Preview

BAYER Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?

BAYER has one hundred and twenty-seven approved drugs.

There are fifty US patents protecting BAYER drugs.

Summary for BAYER
US Patents:50
Tradenames:110
Ingredients:75
NDAs:127
Patent Litigation for BAYER: See patent lawsuits for BAYER

Drugs and US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Pharms HC #4 hydrocortisone CREAM;TOPICAL 080438-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Pharms DELTA-DOME prednisone TABLET;ORAL 080293-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 AB RX No No 7,163,931 ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Pharms MEZLIN mezlocillin sodium monohydrate INJECTABLE;INJECTION 062697-002 Jan 22, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare LEVLITE ethinyl estradiol; levonorgestrel TABLET;ORAL-28 020860-002 Jul 13, 1998 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare NATAZIA dienogest; estradiol valerate TABLET;ORAL 022252-001 May 6, 2010 RX Yes Yes 8,071,577 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 RE43916 ➤ Try a Free Trial
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 7,399,772 ➤ Try a Free Trial
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 4,808,583*PED ➤ Try a Free Trial
Bayer Hlthcare MAGNEVIST gadopentetate dimeglumine INJECTABLE;INJECTION 019596-001 Jun 2, 1988 4,647,447 ➤ Try a Free Trial
Bayer Pharms BAYCOL cerivastatin sodium TABLET;ORAL 020740-006 Jul 24, 2000 5,006,530 ➤ Try a Free Trial
Bayer Hlthcare MYCELEX clotrimazole TROCHE/LOZENGE;ORAL 018713-001 Jun 17, 1983 3,705,172 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Gel 15% ➤ Subscribe 2012-07-27
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Gel 0.05% ➤ Subscribe 2010-12-01
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Topical Foam 15% ➤ Subscribe 2017-09-14
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
Premature patent expirations for BAYER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for BAYER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,704,999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
9,682,021 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses ➤ Try a Free Trial
7,780,986 Method of preparing sustained-release preparations of quinolone antibiotics ➤ Try a Free Trial
8,840,869 Body cavity foams ➤ Try a Free Trial
7,838,541 Aryl ureas with angiogenesis inhibiting activity ➤ Try a Free Trial
6,517,847 Topical gel delivery system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for BAYER Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0814 Netherlands ➤ Try a Free Trial PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
/2006 Austria ➤ Try a Free Trial PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2013025,C1304992 Lithuania ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
323 Luxembourg ➤ Try a Free Trial PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
00597 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
91020-8 0090020-9 Sweden ➤ Try a Free Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Cipla
Moodys
Covington
Express Scripts
Cantor Fitzgerald
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.